Case Report

Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi)

Figure 2

Platelet count response to therapy. Platelets decreased to less than 10,000/μL with mivebresib 1.5 mg once daily monotherapy. Platelets increased to greater than 10,000/μL with a change in mivebresib dosing to 3 mg MWF and increased further to greater than 50,000/μL with the addition of eltrombopag. Platelet counts remained greater than 15,000/μL and up to 120,000/μL with the combination mivebresib and venetoclax and sustained with eltrombopag.